{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=15%25+protein", "query": { "intervention": "15% protein" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2838, "total_pages": 284, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=15%25+protein&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-18T17:39:17.251Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00488982", "title": "Intermittent Chemotherapy With or Without Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Metastatic Hormone Refractory Prostate Cancer (HRPC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostate Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Docetaxel and GM-CSF", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of California, San Francisco", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 125, "start_date": "2007-04", "completion_date": "2014-05", "has_results": true, "last_update_posted_date": "2019-11-20", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 4, "location_summary": "San Francisco, California • Boston, Massachusetts • Portland, Oregon + 1 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Portland", "state": "Oregon" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00488982" }, { "nct_id": "NCT03636503", "title": "Rituximab + Immunotherapy in Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Follicular Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Utomilumab", "type": "DRUG" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "PF04518600", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2018-10-30", "completion_date": "2023-07-30", "has_results": true, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 6, "location_summary": "Duarte, California • New Haven, Connecticut • Atlanta, Georgia + 3 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03636503" }, { "nct_id": "NCT02519322", "title": "Neoadjuvant and Adjuvant Checkpoint Blockade", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cutaneous Melanoma", "Mucosal Melanoma", "Ocular Melanoma", "Stage III Acral Lentiginous Melanoma AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIB Uveal Melanoma AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IIIC Uveal Melanoma AJCC v7", "Stage IV Acral Lentiginous Melanoma AJCC v6 and v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Uveal Melanoma AJCC v7" ], "interventions": [ { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Relatlimab", "type": "BIOLOGICAL" }, { "name": "Therapeutic Conventional Surgery", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2016-02-02", "completion_date": "2023-01-26", "has_results": true, "last_update_posted_date": "2024-04-05", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 2, "location_summary": "New York, New York • Houston, Texas", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02519322" }, { "nct_id": "NCT04607772", "title": "Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Relapsed or Refractory Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Selinexor", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Polatuzumab Vedotin", "type": "DRUG" }, { "name": "Ibrutinib", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Tafasitamab", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Karyopharm Therapeutics Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2020-11-18", "completion_date": "2025-12", "has_results": false, "last_update_posted_date": "2025-10-03", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 18, "location_summary": "Tucson, Arizona • Encinitas, California • La Jolla, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04607772" }, { "nct_id": "NCT07221162", "title": "A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Aluminum Hydroxide Suspension", "type": "DRUG" }, { "name": "Boost-2867", "type": "BIOLOGICAL" }, { "name": "CpG 7909", "type": "BIOLOGICAL" }, { "name": "Sodium Chloride, 0.9%", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 140, "start_date": "2025-12-05", "completion_date": "2026-11-24", "has_results": false, "last_update_posted_date": "2026-06-23", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 8, "location_summary": "San Francisco, California • Baltimore, Maryland • St Louis, Missouri + 5 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Rochester", "state": "New York" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07221162" }, { "nct_id": "NCT04372927", "title": "ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Locally Advanced Lung Non-Small Cell Carcinoma", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8" ], "interventions": [ { "name": "Cisplatin", "type": "DRUG" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Pemetrexed", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1, "start_date": "2021-12-10", "completion_date": "2022-04-23", "has_results": true, "last_update_posted_date": "2023-06-13", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04372927" }, { "nct_id": "NCT00135941", "title": "Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus" ], "interventions": [ { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin glulisine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 582, "start_date": "2005-08", "completion_date": "2007-09", "has_results": false, "last_update_posted_date": "2009-06-04", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 1, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00135941" }, { "nct_id": "NCT01669980", "title": "Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Complicated Community Acquired Pneumonia (CABP)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infections", "Pneumonia" ], "interventions": [ { "name": "Ceftaroline fosamil", "type": "DRUG" }, { "name": "IV Ceftriaxone and Vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Forest Laboratories", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Months", "maximum_age": "18 Years", "sex": "ALL", "summary": "2 Months to 18 Years" }, "enrollment_count": 40, "start_date": "2012-10", "completion_date": "2014-08", "has_results": false, "last_update_posted_date": "2015-11-02", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 13, "location_summary": "Long Beach, California • Oakland, California • Orange County, California + 10 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Orange County", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01669980" }, { "nct_id": "NCT02096354", "title": "A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Colorectal Neoplasms" ], "interventions": [ { "name": "RRx-001", "type": "DRUG" }, { "name": "Regorafenib", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EpicentRx, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 62, "start_date": "2014-05", "completion_date": "2020-10-08", "has_results": true, "last_update_posted_date": "2024-10-15", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 5, "location_summary": "La Jolla, California • Stanford, California • Honolulu, Hawaii + 2 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Rockville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT02096354" }, { "nct_id": "NCT05685602", "title": "CA-4948 Added to Standard Chemotherapy to Treat Metastatic or Unresectable Pancreatic Cancer", "overall_status": "SUSPENDED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Pancreatic Ductal Adenocarcinoma", "Stage III Pancreatic Cancer AJCC v8", "Stage IV Pancreatic Cancer AJCC v8", "Unresectable Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Emavusertib", "type": "BIOLOGICAL" }, { "name": "Gemcitabine Hydrochloride", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2023-06-12", "completion_date": "2027-04-30", "has_results": false, "last_update_posted_date": "2026-09-09", "last_synced_at": "2026-09-18T17:39:17.251Z", "location_count": 26, "location_summary": "Duarte, California • Irvine, California • Orange, California + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05685602" } ] }